Detail of "118292-41-4"

Reference

Efficacy of 0

Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. Phillips, Tania J.; Gottlieb, Alice B.; Leyden, James J.; Lowe, Nicholas J.; Lew-Kaya, Deborah A.; Sefton, John; Walker, Patricia S.; Gibson, John R.; Buntin, Denise M.; Fisher, George Burch, Jr.; Coleman, William P., III; Funicella, Toni; Heffernan, Michael P.; Levine, Norman; Loss, Robert W., Jr.; Phillips, Tania J.; Silvis, Nancy G.; Swinyer, Leonard J.; Tashjian, David N.; Washenik, Kenneth J.; Welch, Kevin L.; Wilson, David C. (Tazarotene Cream Photodamage Clinical Study Group; Boston University School of Medicine, Boston, MA, USA). Archives of Dermatology, 138(11), 1486-1493 (English) 2002 American Medical Association. CODEN: ARDEAC. ISSN: 0003-987X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Objective: To det. the efficacy and safety of 0.1% tazarotene cream for the treatment of photodamage. Design: A 24-wk multicenter, double-blind, randomized, vehicle-controlled intervention study followed by a 28-wk open-label extension. Setting: Ambulatory patients in private and institutional practice. Patients: Of 563 patients with facial photodamage, 91% and 86% completed the double-blind and open-label phases, resp. In the double-blind phase, 20 of 283 tazarotene-treated patients and 1 of 280 vehicle-treated patients discontinued treatment owing to adverse events. Intervention: Once-daily application of 0.1% tazarotene cream or nonmedicated vehicle cream to the face for 24 wk. Then, all continuing patients received treatment with 0.1% tazarotene cream for another 28 wk. Main Outcome Measures: Primarily, fine wrinkling and mottled hyperpigmentation.There are some commonly used reagents with their cas registry numbers 118292-40-3 and 118292-41-4 in this article. Also, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, telangiectasia, actinic keratoses, overall integrated assessment of photodamage, global response to treatment, patients' overall assessment of photodamage, and plasma levels of tazarotenic acid. Results: Compared with the vehicle, at week 24 tazarotene resulted in a significantly greater incidence of patients achieving treatment success (350% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage (P<.01). Addnl. clin. improvement occurred with continued tazarotene treatment and had not plateaued by week 52. Plasma tazarotenic acid concns. did not exceed 0.71 ng/mL. Conclusions: Once-daily applications of 0.1% tazarotene cream significantly reduced multiple signs of photodamage. Plasma levels of tazarotenic acid remained below those of endogenous retinoids. .

Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug

Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug. Hughes, Patrick M.; Olejnik, Orest (Allergan, Inc., USA). U.S. Pat. Appl. Publ. US 2005009910 A1 13 Jan 2005, 18 pp. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K031-557. ICS: A61K031-203. APPLICATION: US 2003-617468 10 Jul 2003. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) The present invention relates to method of sustained-delivery of an active drug to a posterior part of an eye of a mammal to treat or prevent a disease or condition affecting said mammal, wherein said disease or condition can be treated or prevented by the action of said active drug upon said posterior part of the eye, comprising administering an effective amt. 118292-41-4 and 118292-40-3 are also in the experiment. of an ester prodrug of the active drug subconjunctivally or periocularly. Preferably, the active drug is more than about 10 times as active as the prodrug. Other aspects of this invention deal with the treatment of certain diseases by the periocular or subconjunctival delivery of an ester prodrug, and certain pharmaceutical products contg. ester prodrugs for periocular or subconjunctival administration. Microspheres were prepd. with tazarotene, poly(lactide-co-glycolide), polyvinyl alc., methylene chloride, and water for subonjunctival administration. .